Bifurcation Lesions Treatment Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The Bifurcation Lesions Treatment Market is Segmented by Treatment Strategy (One-Stent Strategy, Two-Stent Strategy), Product Type (Drug-Eluting Stents (DES), and More), Lesion Location (Left Main Coronary Bifurcation Lesions, and More), Application (Percutaneous Coronary Intervention (PCI), Peripheral Vascular Intervention (PVI)), End-User (Hospitals, and More), and Geography (North America, Europe, and More). Market Value (USD).

Bifurcation Lesions Treatment Market Size and Share

Bifurcation Lesions Treatment Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Bifurcation Lesions Treatment Market Analysis by Mordor Intelligence

The Bifurcation Lesions Treatment Market size is expected to increase from USD 2.69 billion in 2026 to USD 2.82 billion in 2027 and reach USD 3.70 billion by 2032, growing at a CAGR of 5.58% over 2027-2032.

Growth reflects a rising burden of ischemic heart disease and more frequent use of complex coronary interventions. Imaging, physiology assessment, and adjunct balloons increase the number of devices used in a single procedure. In the United States, intravascular imaging use in PCI rose from 15% in 2016 to nearly 30% in 2023, while combined imaging and physiology use was linked with lower 2-year major adverse cardiovascular event rates and lower long-term costs than angiography alone. The bifurcation lesions treatment market is also being shaped by guideline-supported imaging, outpatient treatment for selected cases, and products that support side-branch treatment. Competition increasingly centers on complete procedure platforms rather than stents alone.

Key Report Takeaways

  • By treatment strategy, the one-stent strategy held 52.15% of the bifurcation lesions treatment market share in 2026, while the two-stent strategy is forecast to grow at a 6.14% CAGR through 2032.
  • By product type, drug-eluting stents (DES) held 38.71% of the bifurcation lesions treatment market share in 2026, while bare-metal stents are expected to grow at a 6.73% CAGR through 2032.
  • By lesion location, left main coronary bifurcation lesions held 39.27% revenue share in 2026, while peripheral bifurcation lesions are forecast to grow at a 7.82% CAGR through 2032.
  • By application, percutaneous coronary intervention (PCI) held a 53.04% revenue share in 2026 and is expected to be the fastest-growing application, growing at an 8.23% CAGR through 2032.
  • By end-user, hospitals held a 43.63% revenue share in 2026, while cardiac specialty centers are forecast to grow at a 7.22% CAGR through 2032.
  • By geography, North America held a 46.24% revenue share in 2026, while Asia-Pacific is projected to grow at a 9.24% CAGR through 2032.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

Bifurcation Lesions Treatment Market Segment Analysis

By Treatment Strategy:

One-Stent Strategies Lead While Two-Stent Use Expands in Selected Cases

One-stent strategy accounted for 52.15% of revenue in 2026. Their leading position reflects evidence that provisional stenting reduces procedural complexity and can lower periprocedural myocardial infarction risk in many non-true bifurcations. The approach is supported by device ecosystems designed around single-stent workflows.

The two-stent strategy is projected to grow at a 6.14% CAGR from 2027 to 2032. Growth is concentrated in true bifurcation anatomy with long side-branch involvement. Imaging-guided assessment helps operators identify the cases where an upfront two-stent strategy is clinically appropriate. A 2026 meta-analysis of 10 randomized trials involving 2,500 patients found dedicated bifurcation stents clinically comparable to conventional drug-eluting stents at 1-year and 4-year endpoints. The evidence supports their use in selected cases, although it does not show clinical superiority over conventional DES.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Bifurcation Lesions Treatment Market Share by Type, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Product Type:

Drug-Eluting Stents Anchor Revenue While Drug-Coated Balloons Change Side-Branch Treatment

Drug-eluting stents accounted for 38.71% of the bifurcation lesions treatment market by product type in 2026. They remain the reference treatment for the main branch in both one-stent and two-stent procedures. Guidewires, balloons, and microcatheters are essential complements to stent placement. Their use rises as procedural complexity increases. Atherectomy devices also have a role in calcified lesions that require preparation before stent delivery.

Bare-metal stents are forecasted to grow at 6.73% CAGR through 2032. This pattern is used as a main-branch scaffold in hybrid drug-coated balloon procedures. The hybrid approach can avoid placing a second permanent implant in the side branch. A 2026 stentless PCI study reported 87.3% freedom from target vessel failure and 92.6% target vessel revascularization at 1 year, without side-branch flow disturbance. These findings suggest that selected anatomies may use fewer DES per procedure over time.

By Lesion Location:

Left Main Coronary Procedures Lead While Peripheral Cases Gain Attention

Left main coronary bifurcation lesions accounted for 39.27% of revenue in 2026. Coronary cases generally use a wider set of devices than peripheral procedures. A typical coronary procedure may include a DES, guidewire, imaging catheter, and a drug-coated balloon or physiology wire. Left-main lesions have particularly high device use because they often require imaging, extended procedure time, and a two-stent approach.

Peripheral bifurcation lesions are forecasted to grow at a 7.82% CAGR from 2027 to 2032. Greater awareness of peripheral artery disease and expanded ankle-brachial index screening support this growth. Aortoiliac procedures using a kissing-stent technique can require bilateral iliac stents. Manufacturers are investing in peripheral balloon and stent profiles to diversify beyond the more competitive coronary bifurcation lesions treatment market.

By Application:

PCI Remains the Primary Source of Demand

Percutaneous coronary intervention (PCI) accounted for 53.04% of the bifurcation lesions treatment market by application in 2026. Coronary bifurcation anatomy represents a large share of clinical caseloads. PCI also benefits from the broadest device ecosystem for procedure planning and optimization. Peripheral vascular intervention serves a smaller but expanding population of patients with peripheral artery disease.

PCI is also expected to be the fastest-growing application, growing at an 8.23% CAGR through 2032. Rising coronary disease volumes support procedure demand. Imaging, physiology assessment, and adjunct balloon use can also increase device consumption per PCI case. Current recommendations for intravascular imaging in complex PCI strengthen the clinical basis for these tools. The resulting demand extends to diagnostic and therapeutic products, rather than only stents.

Segment this market the way your business does.

Get tailored market insights for your requirements.

Bifurcation Lesions Treatment Market Share by Application, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By End-User:

Hospitals Lead While Cardiac Specialty Centers Grow Faster

Hospitals accounted for 43.63% of revenue in 2026. They remain the principal setting for high-acuity coronary cases that need surgical backup, intensive care, and full catheterization laboratory resources. Academic and research institutes play a smaller role in purchasing volume. However, they are often early adopters of imaging systems and specialized bifurcation devices. Their clinical research can shape later purchasing decisions at community hospitals.

Cardiac specialty centers are forecasted to grow at a 7.22% CAGR from 2027 to 2032. Lower-complexity bifurcation PCI cases are moving toward outpatient cardiac facilities. Stable and predictable cases are more suitable for these settings than high-risk lesions. Greater operator experience and AI-assisted OCT guidance may help reduce variation in technique selection. This increases the relevance of specialty centers to the bifurcation lesions industry.

Geography Analysis

North America

North America accounted for 46.24% of revenue in 2026. High PCI procedure density, hospital reimbursement, and rapid uptake of imaging technologies support its leading position. The United States is the largest national contributor in the region. Guideline support for intravascular imaging in complex PCI has reinforced investment in catheterization laboratory equipment. Medtronic completed its acquisition of CathWorks for USD 585 million in April 2026, adding FFRangio physiology assessment from routine angiograms to its cardiovascular portfolio. Canada and Mexico have growing PCI infrastructure, though reimbursement alignment is less consistent.

Asia-Pacific

Asia-Pacific is projected to grow at a 9.24% CAGR from 2027 to 2032. The region benefits from rising cardiovascular disease, broader access to care, and investment in tertiary cardiac facilities. Japan and South Korea are technical leaders but use different approaches to imaging and physiology assessment. China is expanding procedure access through national procurement, even as stent prices face pressure. MicroPort reported that its coronary stent systems surpassed 10 million cumulative global shipments in October 2025. India is expanding PCI access through Ayushman Bharat and private hospital growth in tier-2 and tier-3 cities.

Europe, Middle East and Africa, and South America

Europe is the second-largest region. Post-market follow-up obligations under EU MDR influence implantable cardiac device registration timelines. The European Bifurcation Club’s MADS-2 classification supports greater consistency in procedure selection across major markets. The bifurcation lesions treatment market in the Middle East and Africa remains smaller but is expanding with healthcare infrastructure investment in Saudi Arabia and the UAE. South America has an early-stage but relevant opportunity, particularly in Brazil and Argentina. Public reimbursement in Brazil supports standard coronary stenting but does not consistently cover premium imaging or dedicated bifurcation devices, creating different access levels across care settings.

Bifurcation Lesions Treatment Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

Bifurcation Lesions Treatment Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The bifurcation lesions treatment market is moderately consolidated among global device companies. Abbott, Boston Scientific, and Medtronic lead through their DES portfolios and broader procedure platforms. MicroPort, OrbusNeich, Biotronik, B. Braun, and Meril Life Sciences compete through price-performance positions in Asia-Pacific, the Middle East, and emerging hospital markets. Major companies increasingly combine imaging, physiology, and therapy products within catheterization laboratory partnerships. This strategy reduces reliance on stent specifications as the only source of differentiation.

Medtronic added CathWorks in April 2026 for USD 585 million. The acquisition brings angiogram-based physiology assessment into Medtronic’s interventional cardiology portfolio. Advanced Bifurcation Systems acquired Svelte Medical Systems’ FDA-approved DES assets in April 2026, supporting its path toward a dedicated bifurcation DES platform. These moves show that the bifurcation lesions treatment market is moving toward integrated procedure support.

Product opportunities remain in dedicated peripheral configurations for aortoiliac and femoro-profunda anatomy. MicroPort’s Firelimus and Medtronic’s Prevail support greater use of drug-coated balloons in bifurcation treatment. Smaller suppliers need compatible imaging and physiology pathways to compete in high-volume accounts. Regulatory acceleration pathways in China and the United States can help incumbents and specialists bring new platforms forward. The Bifurcation lesions industry, therefore, remains shaped by both device technology and procedural workflow integration.

Bifurcation Lesions Treatment Industry Leaders

  1. Abbott Laboratories

  2. Boston Scientific Corporation

  3. Medtronic plc

  4. Terumo Corporation

  5. B. Braun Melsungen AG

  6. *Disclaimer: Major Players sorted in no particular order

Bifurcation Lesions Treatment Market Companies Covered in this Report

  • Abbott Laboratories
  • Advanced Bifurcation Systems
  • B. Braun
  • Biosensors International Group, Ltd.
  • BIOTRONIK
  • Boston Scientific
  • Cook Group
  • Cordis
  • Elixir Medical
  • InspireMD, Inc.
  • Johnson & Johnson MedTech
  • Medinol Ltd.
  • Medtronic
  • Meril Life Science
  • MicroPort
  • OrbusNeich Medical Company Limited
  • Sahajanand Medical Technologies (SMT) Pvt. Ltd.
  • Svelte Medical Systems, Inc.
  • Terumo
  • Tryton Medical, Inc.

Recent Industry Developments in Bifurcation Lesions Treatment Market

  • October 2026: W. L. Gore & Associates' medical business announced that the U.S. Food and Drug Administration approved an expanded indication for the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) for use in fenestrated and branched endovascular aortic repair (FEVAR and BEVAR).
  • April 2026: Advanced Bifurcation Systems Inc., a provider of innovative solutions for treating bifurcation lesions in coronary angioplasty, acquired all assets of Svelte Medical Systems, Inc.

Table of Contents for Bifurcation Lesions Treatment Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growth in Complex Percutaneous Coronary Intervention
    • 4.2.2 Expansion of Intravascular Imaging-Guided Procedures
    • 4.2.3 Shift Toward Drug-Eluting and Lower-Profile Stent Platforms
    • 4.2.4 Rising Cardiovascular Disease and High-Risk Patient Burden
    • 4.2.5 Increasing Use of Dedicated Side-Branch Access Technologies
    • 4.2.6 Greater Use of Physiology and Imaging to Select Side-Branch Treatment
  • 4.3 Market Restraints
    • 4.3.1 Procedural Complexity and Operator Training Requirements
    • 4.3.2 High Device, Imaging, and Procedure Costs
    • 4.3.3 Reimbursement Variation for Complex Bifurcation PCI
    • 4.3.4 Limited Standardization of Dedicated Device Workflows Across Cath Labs
  • 4.4 Supply Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Treatment Strategy
    • 5.1.1 One-Stent Strategy
    • 5.1.2 Two-Stent Strategy
  • 5.2 By Product Type
    • 5.2.1 Drug-Eluting Stents (DES)
    • 5.2.2 Bare-Metal Stents (BMS)
    • 5.2.3 Balloon Catheters
    • 5.2.4 Guidewires
    • 5.2.5 Microcatheters
    • 5.2.6 Atherectomy Devices
    • 5.2.7 Other Product Types
  • 5.3 By Lesion Location
    • 5.3.1 Left Main Coronary Bifurcation Lesions
    • 5.3.2 Non-Left Main Coronary Bifurcation Lesions
    • 5.3.3 Peripheral Bifurcation Lesions
  • 5.4 By Application
    • 5.4.1 Percutaneous Coronary Intervention (PCI)
    • 5.4.2 Peripheral Vascular Intervention (PVI)
  • 5.5 By End-User
    • 5.5.1 Hospitals
    • 5.5.2 Cardiac Specialty Centers
    • 5.5.3 Ambulatory Surgical Centers (ASCs)
    • 5.5.4 Academic & Research Institutes
  • 5.6 By Geography
    • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
    • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
    • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
    • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
    • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 Advanced Bifurcation Systems
    • 6.3.3 B. Braun Melsungen AG
    • 6.3.4 Biosensors International Group, Ltd.
    • 6.3.5 Biotronik SE & Co. KG
    • 6.3.6 Boston Scientific Corporation
    • 6.3.7 Cook Medical LLC
    • 6.3.8 Cordis Corporation
    • 6.3.9 Elixir Medical Corporation
    • 6.3.10 InspireMD, Inc.
    • 6.3.11 Johnson & Johnson MedTech
    • 6.3.12 Medinol Ltd.
    • 6.3.13 Medtronic plc
    • 6.3.14 Meril Life Sciences Pvt. Ltd.
    • 6.3.15 MicroPort Scientific Corporation
    • 6.3.16 OrbusNeich Medical Company Limited
    • 6.3.17 Sahajanand Medical Technologies (SMT) Pvt. Ltd.
    • 6.3.18 Svelte Medical Systems, Inc.
    • 6.3.19 Terumo Corporation
    • 6.3.20 Tryton Medical, Inc.

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment

Global Bifurcation Lesions Treatment Market Report Scope

According to the report’s scope, the bifurcation lesions treatment market refers to the global market for interventional cardiology devices and techniques designed to treat coronary artery bifurcation lesions, where a blockage occurs at or near the branching of a main vessel and a side branch. This market encompasses specialized stents, balloons, and procedural strategies (e.g., provisional stenting, double‑stent techniques) that improve patient outcomes in complex percutaneous coronary interventions (PCI).

The bifurcation lesions treatment market is segmented into treatment strategy, product type, lesion location, application, end-user, and geography. By treatment strategy, the market is segmented into one-stent strategy and two-stent strategy. By product type, the market is segmented into drug-eluting stents (DES), bare-metal stents (BMS), balloon catheters, guidewires, microcatheters, atherectomy devices, and other product types. By lesion location, the market is segmented into left main coronary bifurcation lesions, non-left main coronary bifurcation lesions, and peripheral bifurcation lesions. By application, the market is segmented into percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI). By end-user, the market is segmented into hospitals, cardiac specialty centers, ambulatory surgical centers (ASCs), and academic & research institutes. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers values (USD) for all the above segments. 

Segmentation Overview

By Treatment Strategy
Bifurcation Lesions Treatment Market segmentation breakdown
One-Stent Strategy
Two-Stent Strategy
By Product Type
Bifurcation Lesions Treatment Market segmentation breakdown
Drug-Eluting Stents (DES)
Bare-Metal Stents (BMS)
Balloon Catheters
Guidewires
Microcatheters
Atherectomy Devices
Other Product Types
By Lesion Location
Bifurcation Lesions Treatment Market segmentation breakdown
Left Main Coronary Bifurcation Lesions
Non-Left Main Coronary Bifurcation Lesions
Peripheral Bifurcation Lesions
By Application
Bifurcation Lesions Treatment Market segmentation breakdown
Percutaneous Coronary Intervention (PCI)
Peripheral Vascular Intervention (PVI)
By End-User
Bifurcation Lesions Treatment Market segmentation breakdown
Hospitals
Cardiac Specialty Centers
Ambulatory Surgical Centers (ASCs)
Academic & Research Institutes
By Geography
Bifurcation Lesions Treatment Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Bifurcation Lesions Treatment Market segmentation breakdown
By Treatment Strategy One-Stent Strategy
Two-Stent Strategy
By Product Type Drug-Eluting Stents (DES)
Bare-Metal Stents (BMS)
Balloon Catheters
Guidewires
Microcatheters
Atherectomy Devices
Other Product Types
By Lesion Location Left Main Coronary Bifurcation Lesions
Non-Left Main Coronary Bifurcation Lesions
Peripheral Bifurcation Lesions
By Application Percutaneous Coronary Intervention (PCI)
Peripheral Vascular Intervention (PVI)
By End-User Hospitals
Cardiac Specialty Centers
Ambulatory Surgical Centers (ASCs)
Academic & Research Institutes
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is driving demand for the bifurcation lesion treatment market?

Rising cardiovascular disease and wider use of intravascular imaging are supporting demand for stents, imaging catheters, and adjunct tools. The market value is expected to grow from USD 2.69 billion in 2026 to USD 2.82 billion in 2027 to reach USD 3.70 billion by 2032, from 2027 to 2032.

Which treatment strategy is most common for bifurcation lesions?

One-stent strategy led with 52.15% revenue share in 2026 because provisional stenting remains suitable for many non-true bifurcations.

Where are bifurcation procedures increasingly being performed?

Hospitals remain the largest end-user setting, while cardiac specialty centers are projected to grow at a 7.22% CAGR as selected lower-complexity cases move to outpatient.

Which region is expanding fastest for bifurcation treatment?

Asia-Pacific is projected to expand at a 9.24% CAGR from 2027 to 2032, supported by growing cardiac care access and infrastructure.

Page last updated on: